{
    "name": "pertuzumab",
    "comment": "Rx",
    "other_names": [
        "Perjeta"
    ],
    "classes": [
        "Antineoplastics",
        "Anti-HER2",
        "Antineoplastics",
        "Monoclonal Antibody"
    ],
    "source": "https://reference.medscape.com/drug/perjeta-pertuzumab-999749",
    "pregnancy": {
        "common": [
            "There is a pregnancy pharmacovigilance program for therapy administered during pregnancy, or if patient becomes pregnant while receiving therapy or within 7 months following last dose in combination with trastuzumab, health care providers and patients should immediately report exposure to Genentech at 1-888-835-2555",
            "Based on its mechanism of action and findings in animal studies, therapy can cause fetal harm when administered to a pregnant woman; there are no available data on use of drug in pregnant women; however, in post-marketing reports, use of another HER2/neu receptor antagonist (trastuzumab) during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death",
            "Monitor women who received drug in combination with trastuzumab during pregnancy or within 7 months prior to conception for oligohydramnios; if oligohydramnios occurs, perform fetal testing that is appropriate for gestational age and consistent with community standards of care",
            "Verify pregnancy status of females of reproductive potential prior to initiation of therapy",
            "Based on mechanism of action and animal data, drug can cause embryo-fetal harm when administered during pregnancy; advise females of reproductive potential to use effective contraception during treatment and for 7 months following last dose in combination with trastuzumab"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In an animal reproduction study, administration to pregnant cynomolgus monkeys during period of organogenesis resulted in oligohydramnios, delayed  fetal kidney development, and embryo-fetal deaths at clinically relevant exposures that were  2.5 to 20-fold greater than exposures in humans receiving the recommended dose, based on Cmax; apprise patient of potential risks to a fetus; there are clinical  considerations if drug in combination with trastuzumab is used during pregnancy or within  7 months prior to conception"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information regarding presence of drug in human milk, effects on breastfed infant or on milk production; published data suggest that human IgG is present in human milk but does not enter neonatal and infant circulation in substantial amounts; consider developmental and health benefits of breast feeding along with motherâ€™s clinical need for treatment and any potential adverse effects on breastfed child or from underlying maternal condition; consideration should also take into account elimination half-life of pertuzumab and trastuzumab wash out period of 7 months"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Left ventricular dysfunction (LVEF)",
                    "description": [
                        "Subclinical and clinical cardiac failure manifesting as decreased LVEF and CHF may occur with pertuzumab therapy",
                        "Evaluate cardiac function prior to and during treatment",
                        "Discontinue treatment for a confirmed clinically significant decrease in left ventricular function"
                    ]
                },
                {
                    "type": "Embryo-fetal toxicity",
                    "description": [
                        "Exposure to pertuzumab can result in embryo-fetal death and birth defects",
                        "Advise patients of these risks and the need for effective contraception",
                        "Also see Pregnancy"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Alopecia",
            "percent": "61"
        },
        {
            "name": "Diarrhea",
            "percent": "67"
        },
        {
            "name": "Nausea",
            "percent": "42"
        },
        {
            "name": "Neutropenia",
            "percent": "53"
        },
        {
            "name": "Fatigue",
            "percent": "37"
        },
        {
            "name": "Rash",
            "percent": "34"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "32"
        },
        {
            "name": "Decreased appetite",
            "percent": "29"
        },
        {
            "name": "Mucosal inflammation",
            "percent": "28"
        },
        {
            "name": "Asthenia",
            "percent": "26"
        },
        {
            "name": "Vomiting",
            "percent": "24"
        },
        {
            "name": "Peripheral edema",
            "percent": "23"
        },
        {
            "name": "Nail disorder",
            "percent": "23"
        },
        {
            "name": "Myalgia",
            "percent": "23"
        },
        {
            "name": "Anemia",
            "percent": "23"
        },
        {
            "name": "Headache",
            "percent": "21"
        },
        {
            "name": "Stomatitis",
            "percent": "19"
        },
        {
            "name": "Pyrexia",
            "percent": "19"
        },
        {
            "name": "Dysgeusia",
            "percent": "18"
        },
        {
            "name": "Leukopenia",
            "percent": "18"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "17"
        },
        {
            "name": "Constipation",
            "percent": "15"
        },
        {
            "name": "Arthralgia",
            "percent": "15"
        },
        {
            "name": "Dyspnea",
            "percent": "14"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "14"
        },
        {
            "name": "Increased lacrimation",
            "percent": "14"
        },
        {
            "name": "Pruritus",
            "percent": "14"
        },
        {
            "name": "Insomnia",
            "percent": "13"
        },
        {
            "name": "Dizziness",
            "percent": "13"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "12"
        },
        {
            "name": "Dry skin",
            "percent": "11"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "13"
        },
        {
            "name": "Leukopenia",
            "percent": "12"
        },
        {
            "name": "Fatigue",
            "percent": "2"
        },
        {
            "name": "Asthenia",
            "percent": "2"
        },
        {
            "name": "Anemia",
            "percent": "2"
        },
        {
            "name": "Mucosal inflammation",
            "percent": "1"
        },
        {
            "name": "Pyrexia",
            "percent": "1"
        },
        {
            "name": "Nail disorder",
            "percent": "1"
        },
        {
            "name": "Nausea",
            "percent": "1"
        },
        {
            "name": "Vomiting",
            "percent": "1"
        },
        {
            "name": "Headache",
            "percent": "1"
        },
        {
            "name": "Peripheral edema",
            "percent": "0.5"
        },
        {
            "name": "Stomatitis",
            "percent": "0.5"
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Infusion reactions",
            "percent": null
        },
        {
            "name": "Tumor lysis syndrome",
            "percent": null
        },
        {
            "name": "TLS",
            "percent": null
        }
    ]
}